Discounted Cash Flow
Biodexa Pharmaceuticals Plc. ADR
—
—
⚠ Cash flow predictability 49/100 (moderate) —
FCF YoY std dev 59%,
net income 47% (full history)
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $9.4m | $-39.6m | $-2.2m | -423.5% | — |
| 2017 | $10.3m (9.8%) | $-23.4m (40.9%) | $-17.5m (-685.0%) | -228.1% (46.2%) | — |
| 2018 | $2.6m (-74.5%) | $-16.8m (28.4%) | — | -639.8% (-180.5%) | — |
| 2019 | $911.2k (-65.2%) | $-14.8m (11.9%) | $-8.8m | -1620.6% (-153.3%) | — |
| 2020 | $463.7k (-49.1%) | $-31.7m (-114.9%) | — | -6842.6% (-322.2%) | — |
| 2021 | $781.5k (68.5%) | $-8.3m (74.0%) | — | -1056.4% (84.6%) | — |
| 2022 | $945.0k (20.9%) | $-11.5m (-39.0%) | $-9.6m | -1214.3% (-14.9%) | $-1.55 |
| 2023 | $515.1k (-45.5%) | $-10.1m (11.8%) | $-9.6m (0.3%) | -1964.6% (-61.8%) | $-0.02 (98.7%) |
| 2024 | $515.1k (0.0%) | $-8.1m (20.1%) | $-17.6m (-83.9%) | -1569.3% (20.1%) | $-0.00 (95.0%) |
| 2025 | $515.1k (0.0%) | $-8.8m (-8.5%) | $-8.5m (51.8%) | -1703.1% (-8.5%) | $-0.00 (90.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in GBP. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.